PHARMANIAGA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.34 MYR | +1.49% |
|
+1.49% | -11.69% |
| Apr. 19 | China's drugmakers can't sell mRNA shots but haven't quit yet | RE |
| Mar. 27 | Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -11.69% | 103M | B | ||
| +17.35% | 71.39B | C+ | ||
| +2.39% | 25.1B | C+ | ||
| +5.38% | 8.59B | C | ||
| +6.69% | 8.19B | B | ||
| -20.96% | 7.91B | B- | ||
| +0.49% | 4.54B | B- | ||
| +17.12% | 4.31B | B+ | ||
| -3.38% | 3.93B | B- | ||
| -2.61% | 3.86B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PHARMA Stock
- Ratings Pharmaniaga
